Search Bar & Filters
Found 61 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a phase 3 clinical trial in India to evaluate the safety and immune response of the RSVpreF vaccine in adults. The study aims to learn how well the vaccine works to prevent Respiratory Syncytial Virus RSV infection and to monitor any side effects after vaccination. This trial is double-blinded and placebo-controlled, ensuring unbiased assessment of the vaccines effects. Participants will be randomly assigned to receive either the RSVpreF vaccine or a placebo. The vaccine is given as an injection, and the study compares these two groups to understand the vaccines impact on immune response and safety. The trial includes adults aged 18 and older, including those with certain stable chronic medical conditions that increase their risk of RSV disease. During the study, participants will be closely monitored for local and systemic reactions for 7 days after vaccination and for adverse events up to 3 months post-vaccination. Blood samples will be taken before and 1 month after vaccination to measure neutralizing antibody levels against RSV types A and B. The study tracks serious adverse events and uses these data to evaluate the vaccines immunogenicity and safety over time.
Actively Recruiting
Researchers are evaluating the safety and efficacy of GIA632 in adults aged 18 to 99 years with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled Phase 2b study aims to identify the optimal dose of GIA632 to be further studied in a Phase 3 program. The study also includes an extension period to assess longer-term safety and effectiveness. Participants will be randomly assigned to one of several groups receiving either GIA632 or a placebo during a 48-week core treatment period. The study will measure the dose-response relationship of GIA632 and compare its effects with placebo. The extension phase will further evaluate the safety and efficacy over a longer term. During the study, participants will have regular assessments including measurement of facial and total body vitiligo area using the Vitiligo Area Scoring Index VASI at baseline and multiple time points up to 48 weeks. Researchers will also track improvements using the Vitiligo Noticeability Scale. Safety and treatment response will be monitored throughout the study period, which lasts up to approximately four years including follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are conducting a Phase I open-label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose of AUR107 in adults with relapsed advanced malignancies. The study focuses on patients with selected advanced solid tumors, such as non-small cell lung cancer, gastric cancer, urothelial cancer, kidney cancer, colon cancer, and esophageal cancer, who have no curative or life-prolonging treatment options left. This first-in-human trial aims to find the best dose of AUR107 using a traditional dose-escalation design. Participants will receive oral AUR107 once daily at escalating doses ranging from 5 mg to 200 mg. The trial follows a 33 dose escalation design to evaluate safety and determine the optimal biological dose based on safety, pharmacokinetics, and pharmacodynamics data. The study is multicenter and includes dose expansion following dose escalation. During the study, participants will be closely monitored for dose-limiting toxicities and treatment-related adverse events over 28-day cycles. Researchers will measure pharmacokinetic parameters such as maximum concentration, time to maximum concentration, area under the curve, mean residence time, and elimination half-life at various time points under fasting and fed conditions. Safety assessments and clinical evaluations will be conducted throughout the study, which is expected to continue until June 2027.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose of an oral drug called AUR108 in adult patients with relapsed advanced lymphomas, including Non-Hodgkin and Hodgkin lymphoma. This Phase 1, open-label, first-in-human study focuses on patients who have no available curative or life-prolonging treatments left and have exhausted all effective local therapies. The study uses a traditional dose-escalation design to determine the best dose of AUR108 based on safety and biological data. Participants will receive AUR108 orally with doses planned at 50, 90, 150, 220, and 300 mg in a cycle of 3 days of dosing followed by 4 days off each week. The study follows a 33 dose-escalation method to evaluate safety and drug behavior in the body and to select the optimal biological dose. This is a multicenter trial with dose expansion planned after the initial dose-escalation phase. During the study, participants will be closely monitored for dose-limiting toxicities during the first 28-day cycle and treatment-related adverse events throughout the trial, which may last about a year. Researchers will collect blood samples to measure drug levels and effects at multiple time points, including days 1, 8, and 17. Participants will undergo safety assessments, organ function tests, and evaluations of their lymphoma status to track treatment impact and side effects over time.
1-10 of 61
1